Roth Capital maintains its Buy rating and $10 price target on Curis (Nasdaq: CRIS) following Q4 results. The company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE